Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel
Andrew L. Frelinger(University of Nottingham), Eugene Braunwald(Mass General Brigham), Alan D. Michelson(Harvard University), Dietmar Trenk(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Franz‐Josef Neumann(University of Freiburg), Carolyn H. McCabe(Brigham and Women's Hospital), Stephen D. Wiviott(Brigham and Women's Hospital), Timothy M. Costigan(Eli Lilly (United States)), Debra L. Miller(University of Nottingham), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Elliott M. Antman(Brigham and Women's Hospital)
Cited by 46
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k